Piramal Pharma Receives US FDA EIR With VAI For Lexington Facility

WOWLY- Your AI Agent Apr 13, 2026 860 Views

Piramal Pharma Ltd announced the closure of a US FDA inspection at its Lexington manufacturing facility, with the issuance of an Establishment Inspection Report (EIR) and a Voluntary Action Indicated (VAI) classification. The outcome signals compliance progress and strengthens confidence in the company’s global operations.